Report cover image

Global Neurokinin Receptor Antagonists API Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 215 Pages
SKU # APRC20279830

Description

Summary

According to APO Research, the global Neurokinin Receptor Antagonists API market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Neurokinin Receptor Antagonists API is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Neurokinin Receptor Antagonists API is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Neurokinin Receptor Antagonists API market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Neurokinin Receptor Antagonists API is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Neurokinin Receptor Antagonists API market include Zhejiang Tiantai Pharmaceutical, Humanwell Pharmaceutical, Viwit, Sichuan Qingmu Pharmaceutical, Kelun Pharmaceutical, Shandong New Time Pharmaceutical, Shandong Anxin Pharmaceutical, Qilu Pharmaceutical and Luoxin Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neurokinin Receptor Antagonists API, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Neurokinin Receptor Antagonists API, also provides the sales of main regions and countries. Of the upcoming market potential for Neurokinin Receptor Antagonists API, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurokinin Receptor Antagonists API sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neurokinin Receptor Antagonists API market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neurokinin Receptor Antagonists API sales, projected growth trends, production technology, application and end-user industry.

Neurokinin Receptor Antagonists API Segment by Company

Zhejiang Tiantai Pharmaceutical
Humanwell Pharmaceutical
Viwit
Sichuan Qingmu Pharmaceutical
Kelun Pharmaceutical
Shandong New Time Pharmaceutical
Shandong Anxin Pharmaceutical
Qilu Pharmaceutical
Luoxin Pharmaceuticals
Lianyungang Runzhong Pharmaceutical
Wisdom Pharmaceutical
Hansoh Pharma
United Pharma
Hangzhou Jiuyuan Gene Engineering
Beijing Sjar Technology Development
Zydus Animal Health And Investments
Taizhou Crene Biotechnology
Solara Active Pharma Sciences
Procos
Piramal Pharma
Optimus Pharma
Murli Krishna Pharma
MSN Laboratories
Jubilant Pharmova
Helsinn Advanced Synthesis
Glenmark Life Sciences
Dr. Reddy's Laboratories
Clearsynth Labs
Camus Pharma
Andenex
Neurokinin Receptor Antagonists API Segment by Type

Aprepitant
Fezolinetant
Fosaprepitant
Rolapitant
Maropitant
Netupitant
Neurokinin Receptor Antagonists API Segment by Application

Injections
Tablets
Oral Suspension
Capsules
Other
Neurokinin Receptor Antagonists API Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Neurokinin Receptor Antagonists API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Neurokinin Receptor Antagonists API market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Neurokinin Receptor Antagonists API significant trends, drivers, influence factors in global and regions.
6. To analyze Neurokinin Receptor Antagonists API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurokinin Receptor Antagonists API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurokinin Receptor Antagonists API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurokinin Receptor Antagonists API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurokinin Receptor Antagonists API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurokinin Receptor Antagonists API industry.
Chapter 3: Detailed analysis of Neurokinin Receptor Antagonists API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Neurokinin Receptor Antagonists API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Neurokinin Receptor Antagonists API in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

215 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Neurokinin Receptor Antagonists API Sales Value (2020-2031)
1.2.2 Global Neurokinin Receptor Antagonists API Sales Volume (2020-2031)
1.2.3 Global Neurokinin Receptor Antagonists API Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Neurokinin Receptor Antagonists API Market Dynamics
2.1 Neurokinin Receptor Antagonists API Industry Trends
2.2 Neurokinin Receptor Antagonists API Industry Drivers
2.3 Neurokinin Receptor Antagonists API Industry Opportunities and Challenges
2.4 Neurokinin Receptor Antagonists API Industry Restraints
3 Neurokinin Receptor Antagonists API Market by Company
3.1 Global Neurokinin Receptor Antagonists API Company Revenue Ranking in 2024
3.2 Global Neurokinin Receptor Antagonists API Revenue by Company (2020-2025)
3.3 Global Neurokinin Receptor Antagonists API Sales Volume by Company (2020-2025)
3.4 Global Neurokinin Receptor Antagonists API Average Price by Company (2020-2025)
3.5 Global Neurokinin Receptor Antagonists API Company Ranking (2023-2025)
3.6 Global Neurokinin Receptor Antagonists API Company Manufacturing Base and Headquarters
3.7 Global Neurokinin Receptor Antagonists API Company Product Type and Application
3.8 Global Neurokinin Receptor Antagonists API Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Neurokinin Receptor Antagonists API Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Neurokinin Receptor Antagonists API Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Neurokinin Receptor Antagonists API Market by Type
4.1 Neurokinin Receptor Antagonists API Type Introduction
4.1.1 Aprepitant
4.1.2 Fezolinetant
4.1.3 Fosaprepitant
4.1.4 Rolapitant
4.1.5 Maropitant
4.1.6 Netupitant
4.2 Global Neurokinin Receptor Antagonists API Sales Volume by Type
4.2.1 Global Neurokinin Receptor Antagonists API Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Neurokinin Receptor Antagonists API Sales Volume by Type (2020-2031)
4.2.3 Global Neurokinin Receptor Antagonists API Sales Volume Share by Type (2020-2031)
4.3 Global Neurokinin Receptor Antagonists API Sales Value by Type
4.3.1 Global Neurokinin Receptor Antagonists API Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Neurokinin Receptor Antagonists API Sales Value by Type (2020-2031)
4.3.3 Global Neurokinin Receptor Antagonists API Sales Value Share by Type (2020-2031)
5 Neurokinin Receptor Antagonists API Market by Application
5.1 Neurokinin Receptor Antagonists API Application Introduction
5.1.1 Injections
5.1.2 Tablets
5.1.3 Oral Suspension
5.1.4 Capsules
5.1.5 Other
5.2 Global Neurokinin Receptor Antagonists API Sales Volume by Application
5.2.1 Global Neurokinin Receptor Antagonists API Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Neurokinin Receptor Antagonists API Sales Volume by Application (2020-2031)
5.2.3 Global Neurokinin Receptor Antagonists API Sales Volume Share by Application (2020-2031)
5.3 Global Neurokinin Receptor Antagonists API Sales Value by Application
5.3.1 Global Neurokinin Receptor Antagonists API Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Neurokinin Receptor Antagonists API Sales Value by Application (2020-2031)
5.3.3 Global Neurokinin Receptor Antagonists API Sales Value Share by Application (2020-2031)
6 Neurokinin Receptor Antagonists API Regional Sales and Value Analysis
6.1 Global Neurokinin Receptor Antagonists API Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Neurokinin Receptor Antagonists API Sales by Region (2020-2031)
6.2.1 Global Neurokinin Receptor Antagonists API Sales by Region: 2020-2025
6.2.2 Global Neurokinin Receptor Antagonists API Sales by Region (2026-2031)
6.3 Global Neurokinin Receptor Antagonists API Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Neurokinin Receptor Antagonists API Sales Value by Region (2020-2031)
6.4.1 Global Neurokinin Receptor Antagonists API Sales Value by Region: 2020-2025
6.4.2 Global Neurokinin Receptor Antagonists API Sales Value by Region (2026-2031)
6.5 Global Neurokinin Receptor Antagonists API Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Neurokinin Receptor Antagonists API Sales Value (2020-2031)
6.6.2 North America Neurokinin Receptor Antagonists API Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Neurokinin Receptor Antagonists API Sales Value (2020-2031)
6.7.2 Europe Neurokinin Receptor Antagonists API Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Neurokinin Receptor Antagonists API Sales Value (2020-2031)
6.8.2 Asia-Pacific Neurokinin Receptor Antagonists API Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Neurokinin Receptor Antagonists API Sales Value (2020-2031)
6.9.2 South America Neurokinin Receptor Antagonists API Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Neurokinin Receptor Antagonists API Sales Value (2020-2031)
6.10.2 Middle East & Africa Neurokinin Receptor Antagonists API Sales Value Share by Country, 2024 VS 2031
7 Neurokinin Receptor Antagonists API Country-level Sales and Value Analysis
7.1 Global Neurokinin Receptor Antagonists API Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Neurokinin Receptor Antagonists API Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Neurokinin Receptor Antagonists API Sales by Country (2020-2031)
7.3.1 Global Neurokinin Receptor Antagonists API Sales by Country (2020-2025)
7.3.2 Global Neurokinin Receptor Antagonists API Sales by Country (2026-2031)
7.4 Global Neurokinin Receptor Antagonists API Sales Value by Country (2020-2031)
7.4.1 Global Neurokinin Receptor Antagonists API Sales Value by Country (2020-2025)
7.4.2 Global Neurokinin Receptor Antagonists API Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.5.2 USA Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.6.2 Canada Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.8.2 Germany Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.9.2 France Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.9.3 France Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.11.2 Italy Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.12.2 Spain Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.13.2 Russia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.16.2 China Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.16.3 China Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.17.2 Japan Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.19.2 India Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.19.3 India Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.20.2 Australia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.24.2 Chile Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.26.2 Peru Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.28.2 Israel Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.29.2 UAE Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.31.2 Iran Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Neurokinin Receptor Antagonists API Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Neurokinin Receptor Antagonists API Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Neurokinin Receptor Antagonists API Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Zhejiang Tiantai Pharmaceutical
8.1.1 Zhejiang Tiantai Pharmaceutical Comapny Information
8.1.2 Zhejiang Tiantai Pharmaceutical Business Overview
8.1.3 Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.1.4 Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
8.1.5 Zhejiang Tiantai Pharmaceutical Recent Developments
8.2 Humanwell Pharmaceutical
8.2.1 Humanwell Pharmaceutical Comapny Information
8.2.2 Humanwell Pharmaceutical Business Overview
8.2.3 Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.2.4 Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
8.2.5 Humanwell Pharmaceutical Recent Developments
8.3 Viwit
8.3.1 Viwit Comapny Information
8.3.2 Viwit Business Overview
8.3.3 Viwit Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.3.4 Viwit Neurokinin Receptor Antagonists API Product Portfolio
8.3.5 Viwit Recent Developments
8.4 Sichuan Qingmu Pharmaceutical
8.4.1 Sichuan Qingmu Pharmaceutical Comapny Information
8.4.2 Sichuan Qingmu Pharmaceutical Business Overview
8.4.3 Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.4.4 Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
8.4.5 Sichuan Qingmu Pharmaceutical Recent Developments
8.5 Kelun Pharmaceutical
8.5.1 Kelun Pharmaceutical Comapny Information
8.5.2 Kelun Pharmaceutical Business Overview
8.5.3 Kelun Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.5.4 Kelun Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
8.5.5 Kelun Pharmaceutical Recent Developments
8.6 Shandong New Time Pharmaceutical
8.6.1 Shandong New Time Pharmaceutical Comapny Information
8.6.2 Shandong New Time Pharmaceutical Business Overview
8.6.3 Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.6.4 Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
8.6.5 Shandong New Time Pharmaceutical Recent Developments
8.7 Shandong Anxin Pharmaceutical
8.7.1 Shandong Anxin Pharmaceutical Comapny Information
8.7.2 Shandong Anxin Pharmaceutical Business Overview
8.7.3 Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.7.4 Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
8.7.5 Shandong Anxin Pharmaceutical Recent Developments
8.8 Qilu Pharmaceutical
8.8.1 Qilu Pharmaceutical Comapny Information
8.8.2 Qilu Pharmaceutical Business Overview
8.8.3 Qilu Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.8.4 Qilu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
8.8.5 Qilu Pharmaceutical Recent Developments
8.9 Luoxin Pharmaceuticals
8.9.1 Luoxin Pharmaceuticals Comapny Information
8.9.2 Luoxin Pharmaceuticals Business Overview
8.9.3 Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.9.4 Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Product Portfolio
8.9.5 Luoxin Pharmaceuticals Recent Developments
8.10 Lianyungang Runzhong Pharmaceutical
8.10.1 Lianyungang Runzhong Pharmaceutical Comapny Information
8.10.2 Lianyungang Runzhong Pharmaceutical Business Overview
8.10.3 Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.10.4 Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
8.10.5 Lianyungang Runzhong Pharmaceutical Recent Developments
8.11 Wisdom Pharmaceutical
8.11.1 Wisdom Pharmaceutical Comapny Information
8.11.2 Wisdom Pharmaceutical Business Overview
8.11.3 Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.11.4 Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
8.11.5 Wisdom Pharmaceutical Recent Developments
8.12 Hansoh Pharma
8.12.1 Hansoh Pharma Comapny Information
8.12.2 Hansoh Pharma Business Overview
8.12.3 Hansoh Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.12.4 Hansoh Pharma Neurokinin Receptor Antagonists API Product Portfolio
8.12.5 Hansoh Pharma Recent Developments
8.13 United Pharma
8.13.1 United Pharma Comapny Information
8.13.2 United Pharma Business Overview
8.13.3 United Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.13.4 United Pharma Neurokinin Receptor Antagonists API Product Portfolio
8.13.5 United Pharma Recent Developments
8.14 Hangzhou Jiuyuan Gene Engineering
8.14.1 Hangzhou Jiuyuan Gene Engineering Comapny Information
8.14.2 Hangzhou Jiuyuan Gene Engineering Business Overview
8.14.3 Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.14.4 Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Product Portfolio
8.14.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
8.15 Beijing Sjar Technology Development
8.15.1 Beijing Sjar Technology Development Comapny Information
8.15.2 Beijing Sjar Technology Development Business Overview
8.15.3 Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.15.4 Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Product Portfolio
8.15.5 Beijing Sjar Technology Development Recent Developments
8.16 Zydus Animal Health And Investments
8.16.1 Zydus Animal Health And Investments Comapny Information
8.16.2 Zydus Animal Health And Investments Business Overview
8.16.3 Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.16.4 Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Product Portfolio
8.16.5 Zydus Animal Health And Investments Recent Developments
8.17 Taizhou Crene Biotechnology
8.17.1 Taizhou Crene Biotechnology Comapny Information
8.17.2 Taizhou Crene Biotechnology Business Overview
8.17.3 Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.17.4 Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Product Portfolio
8.17.5 Taizhou Crene Biotechnology Recent Developments
8.18 Solara Active Pharma Sciences
8.18.1 Solara Active Pharma Sciences Comapny Information
8.18.2 Solara Active Pharma Sciences Business Overview
8.18.3 Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.18.4 Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Product Portfolio
8.18.5 Solara Active Pharma Sciences Recent Developments
8.19 Procos
8.19.1 Procos Comapny Information
8.19.2 Procos Business Overview
8.19.3 Procos Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.19.4 Procos Neurokinin Receptor Antagonists API Product Portfolio
8.19.5 Procos Recent Developments
8.20 Piramal Pharma
8.20.1 Piramal Pharma Comapny Information
8.20.2 Piramal Pharma Business Overview
8.20.3 Piramal Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.20.4 Piramal Pharma Neurokinin Receptor Antagonists API Product Portfolio
8.20.5 Piramal Pharma Recent Developments
8.21 Optimus Pharma
8.21.1 Optimus Pharma Comapny Information
8.21.2 Optimus Pharma Business Overview
8.21.3 Optimus Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.21.4 Optimus Pharma Neurokinin Receptor Antagonists API Product Portfolio
8.21.5 Optimus Pharma Recent Developments
8.22 Murli Krishna Pharma
8.22.1 Murli Krishna Pharma Comapny Information
8.22.2 Murli Krishna Pharma Business Overview
8.22.3 Murli Krishna Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.22.4 Murli Krishna Pharma Neurokinin Receptor Antagonists API Product Portfolio
8.22.5 Murli Krishna Pharma Recent Developments
8.23 MSN Laboratories
8.23.1 MSN Laboratories Comapny Information
8.23.2 MSN Laboratories Business Overview
8.23.3 MSN Laboratories Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.23.4 MSN Laboratories Neurokinin Receptor Antagonists API Product Portfolio
8.23.5 MSN Laboratories Recent Developments
8.24 Jubilant Pharmova
8.24.1 Jubilant Pharmova Comapny Information
8.24.2 Jubilant Pharmova Business Overview
8.24.3 Jubilant Pharmova Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.24.4 Jubilant Pharmova Neurokinin Receptor Antagonists API Product Portfolio
8.24.5 Jubilant Pharmova Recent Developments
8.25 Helsinn Advanced Synthesis
8.25.1 Helsinn Advanced Synthesis Comapny Information
8.25.2 Helsinn Advanced Synthesis Business Overview
8.25.3 Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.25.4 Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Product Portfolio
8.25.5 Helsinn Advanced Synthesis Recent Developments
8.26 Glenmark Life Sciences
8.26.1 Glenmark Life Sciences Comapny Information
8.26.2 Glenmark Life Sciences Business Overview
8.26.3 Glenmark Life Sciences Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.26.4 Glenmark Life Sciences Neurokinin Receptor Antagonists API Product Portfolio
8.26.5 Glenmark Life Sciences Recent Developments
8.27 Dr. Reddy's Laboratories
8.27.1 Dr. Reddy's Laboratories Comapny Information
8.27.2 Dr. Reddy's Laboratories Business Overview
8.27.3 Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.27.4 Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Product Portfolio
8.27.5 Dr. Reddy's Laboratories Recent Developments
8.28 Clearsynth Labs
8.28.1 Clearsynth Labs Comapny Information
8.28.2 Clearsynth Labs Business Overview
8.28.3 Clearsynth Labs Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.28.4 Clearsynth Labs Neurokinin Receptor Antagonists API Product Portfolio
8.28.5 Clearsynth Labs Recent Developments
8.29 Camus Pharma
8.29.1 Camus Pharma Comapny Information
8.29.2 Camus Pharma Business Overview
8.29.3 Camus Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.29.4 Camus Pharma Neurokinin Receptor Antagonists API Product Portfolio
8.29.5 Camus Pharma Recent Developments
8.30 Andenex
8.30.1 Andenex Comapny Information
8.30.2 Andenex Business Overview
8.30.3 Andenex Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2020-2025)
8.30.4 Andenex Neurokinin Receptor Antagonists API Product Portfolio
8.30.5 Andenex Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Neurokinin Receptor Antagonists API Value Chain Analysis
9.1.1 Neurokinin Receptor Antagonists API Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Neurokinin Receptor Antagonists API Sales Mode & Process
9.2 Neurokinin Receptor Antagonists API Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Neurokinin Receptor Antagonists API Distributors
9.2.3 Neurokinin Receptor Antagonists API Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.